Denmark’s Genmab (CSE:GMAB) is in advanced talks to acquire Merus NV (NASDAQ:MRUS), a Dutch biotech developing cancer treatments, Bloomberg reported on Sunday, citing people familiar with the matter.
Merus, which is listed on Nasdaq with a market capitalization of about $5.2 billion, has drawn takeover interest from several large drugmakers in recent weeks and could announce a deal within days, the report said.
A potential acquisition would be Genmab’s biggest ever. The Copenhagen-based company has a market value of about $18.5 billion, the report added.
Shares of Merus have rallied since May, when the company reported that its experimental drug, petosemtamab, shrank tumors in head-and-neck cancer patients more effectively than current therapies when paired with Merck’s (NYSE:MRK) Keytruda.
Source :
https://www.investing.com/news/stock-market-news/genmab-in-advanced-talks-to-buy-dutch-drugmaker-merus--bloomberg-4259395
